Esther N. Oliva

Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome

Garrett W. Rhyasen, Lyndsey Bolanos, Jing Fang et al. · Cancer Cell · 2013 · 199 citations · Full text

Hematological Malignancy, Myelodysplastic Syndrome, Immunology +4

Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1

Jing Fang, Garrett W. Rhyasen, Lyndsey Bolanos et al. · Blood · 2012 · 100 citations · Full text

Outcome of therapy-related myeloid neoplasms treated with azacitidine

Luana Fianchi, Marianna Criscuolo, Monia Lunghi et al. · Journal of Hematology & Oncology · 2012 · 55 citations · Full text

Changes in <i>RPS14</i> expression levels during lenalidomide treatment in Low‐ and Intermediate‐1‐risk myelodysplastic syndromes with chromosome 5q deletion

Esther N. Oliva, Maria Cuzzola, Francesco Nobile et al. · European Journal Of Haematology · 2010 · 29 citations

Costs and quality of life in patients with myelodysplastic syndromes.

Carlo Lucioni, Carlo Finelli, S. Mazzi et al. · PubMed · 2013 · 28 citations · Full text

Quality Of Life, Family Medicine, Transfusion Dependence +20